NovoCure's INNOVATE-3 trial fails primary endpoint: no OS benefit in ovarian cancer

NovoCure Ltd

Median OS 12.2 months (TTFields + paclitaxel) vs 11.9 months (paclitaxel alone); HR 1.008.
540 patients enrolled; trial designed for platinum-resistant ovarian cancer.
TTFields therapy well-tolerated without added systemic toxicities.
Exploratory subgroup suggests potential survival benefit in patients with only one prior therapy line.
Full data analysis ongoing; results to be shared with scientific community.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.